Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab

NCT02845999 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Metastatic Cancer

Interventions

BIOLOGICAL: allogenic immunotherapy based on Natural Killer cells adoptive transfer
BIOLOGICAL: cetuximab
DRUG: Cyclophosphamide
DRUG: fludarabine
DRUG: interleukin-2

Sponsor

Centre Hospitalier Universitaire de Besancon

Collaborators

[object Object]